Brief Title: STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors

PRIMARY OUTCOMES

Primary Outcome 1 - Measure:

Primary Outcome 1 - Timeframe: N/A

CONDITION

• Advanced Solid Tumor
• Non Small Cell Lung Cancer
• Head and Neck Squamous Cell Carcinoma
• Malignant Melanoma
• Renal Cell Carcinoma
• Cervical Cancer
• Microsatellite Instability High
• Gastric Cancer
• GastroEsophageal Cancer
• Urothelial Carcinoma
• Mismatch Repair Deficiency

ELIGIBILITY

Selected Inclusion Criteria
1. Patients must have selected tumor types and must have progressed after standard of care treatment, or be intolerant to treatment, or refused standard treatment.

- 2. Patients must be amenable to a fresh tissue biopsy, unless medically contraindicated.

- 3. Patients with central nervous system (CNS) metastases must have been treated and be asymptomatic.
Selected Exclusion Criteria:
1. Received systemic anti-cancer therapy within 3 weeks of the first dose of study treatment or small molecule kinase inhibitors within 6 elimination half-lives of the first dose of study treatment.

- 2. Received radiotherapy within 2 weeks of the first dose of study treatment.

- 3. Received prior IL-2-based or IL-15-based cytokine therapy.

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: N/A

Role: N/A

Affiliation: N/A

Overall Contact

Name: Clinical Operations

Phone: 650-271-9888

Email: clinicaltrialinfo@synthekine.com

LOCATION